Sagent Pharmaceuticals Announces the Launch of Ketorolac Tromethamine Injection, USP

SCHAUMBURG, Ill., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ketorolac Tromethamine Injection, USP, a nonsteroidal anti-inflammatory agent, in three preservative-free glass vials. According to IMS, for the 12 months ending July 2014, the US market for Ketorolac approximated $34 million. As with all products in Sagent's portfolio, Ketorolac features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

About Ketorolac Tromethamine Injection, USP

Ketorolac Tromethamine Injection, USP is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.

The package insert, available at, contains the indications, boxed warning, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 jsinger@sagentpharma.comSource:Sagent Pharmaceuticals, Inc.